An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas

Figure 6

(a) The expression levels of chemokines and their receptor in the low- and high-risk groups. (b) The expression profile of immunomodulators molecule, including MHC molecule, immunostimulator, and immunoinhibitor, in the low- and high-risk groups. (c) Comparison of TMB in the low- and high-risk groups in the CGGA_693 and TCGA cohorts. (d) Chord diagram showing the correlation of the risk score with the expression of several critical immune checkpoint molecules. (e) Boxplot showing significantly different expression levels of immune checkpoint molecules between low- and high-risk groups. (f) Discordance in the enrichment scores of immunotherapy-predicted pathways between low- and high-risk groups in the CGGA_693 cohort.

(a)

(b)

(c)

(d)

(e)

(f)